These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20691745)

  • 1. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
    Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
    Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
    J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients.
    Hori H; Yoshimura R; Katsuki A; Hayashi K; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    Int J Psychiatry Clin Pract; 2012 Jun; 16(2):138-42. PubMed ID: 22136174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients.
    Hori H; Yoshimura R; Katsuki A; Sugita AI; Atake K; Nakamura J
    J Psychiatr Res; 2013 Dec; 47(12):1843-8. PubMed ID: 24054464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
    Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients.
    Hori H; Yoshimura R; Katsuki A; Hayashi K; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    J Psychiatr Res; 2012 Jun; 46(6):757-61. PubMed ID: 22464338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
    Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
    Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.
    Wittorf A; Sickinger S; Wiedemann G; Klingberg S
    Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Premorbid IQ and schizophrenia. Increasing cognitive reduction by episodes.
    Eberhard J; Riley F; Levander S
    Eur Arch Psychiatry Clin Neurosci; 2003 Apr; 253(2):84-8. PubMed ID: 12799746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
    Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.